Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 70

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 70
---
 of the Placement Agent Warrants are substantially
similar to the terms of the Warrants. The offer and sale of the Placement Agent Warrants, as well as the offer and sale of the shares
of our common stock issuable upon exercise thereof, are registered on the registration statement of which this prospectus is a part. The
form of the Placement Agent Warrants is included as an exhibit to this registration statement of which this prospectus forms a part.

Right of First Refusal

We have granted the placement
agent a right of first refusal for a period of twelve (12) months following the closing of this offering to act as sole book-running manager,
sole underwriter or sole placement agent for each and every future public or private offering or other capital-raising financing of equity
or equity-linked securities using an underwriter or placement agent by us or any of our successors or subsidiaries, subject to certain
exceptions.

Tail

We have also agreed to
pay the placement agent a tail fee equal to the cash and warrant compensation in this offering, if any investor, who was wall-crossed
by the placement agent with respect to a non-public offering or had back and forth correspondence with the placement agent with respect
to a public offering of our securities, in each case during the term of its engagement, provides us with capital in any public or private
offering or other financing or capital raising transaction during the twelve-month period following expiration or termination
of our engagement of the placement agent, subject to an exception.

Other Relationships

From time to time, the placement agent may provide in the future,
various advisory, investment and commercial banking and other services to us in the ordinary course of business, for which it may receive
customary fees and commissions. The placement agent acted as our placement agent in connection with the private placement we consummated
in September 2024 and the registered direct offerings we consummated in January 2025 and February 2025, for which it received compensation.
Except as disclosed in this prospectus, we have no present arrangements with the placement agent for any further services.

Determination of Offering Price

The combined offering
price per share and accompanying Warrants and the combined offering price per Pre-Funded Warrants and accompanying Warrants we are
offering and the exercise prices and other terms of the Warrants were negotiated between us and the investors, in consultation with the
placement agent based on the trading of our common stock prior to this offering, among other things. Other factors considered in determining